Abstract
In this chapter, we present the immunological basis of inflammatory arthritides, with a focus on the etiology and pathogenesis of rheumatoid arthritis (RA) and spondyloarthritides (SpA). In genetically predisposed individuals, the initial immunologic events in the pathogenesis of seropositive RA occur in the lungs, where smoking (“first hit”) triggers citrullination of lung proteins and asymptomatic production of ACPA (preclinical RA). Not well-characterized “second hits” trigger a series of immunological events (e.g., changes in the effector functions and antigen specificities of ACPA, cytokine/chemokine production, and activation of resident synovial and endothelial cells) resulting in the onset of early RA. Then, synovial cytokine networks and immune complexes induce perpetuation of synovial inflammation (established RA) with pannus formation, bone and cartilage destruction, systemic osteoporosis, and extra-articular comorbidities (premature atherosclerosis and cardiovascular events). All SpA endotypes display strong polygenic heritability, with HLA-B27 conferring the highest risk. Type 3 inflammation (IL-23/IL-17 pathway) is central in SpA pathogenesis, with IL-17 and IL-23 playing tissue/organ-specific roles. In SpA pathogenesis, there is a mechanistic link between repeated mechano-inflammation in the entheses and events occurring in the gut (gut-joint axis), such as epithelial barrier disruption, dysbiosis, intestinal inflammation, and arthritogenic priming of the immune system.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Landre-Beauvais AJ. The first description of rheumatoid arthritis. Unabridged text of the doctoral dissertation presented in 1800. Joint Bone Spine. 2001;68:130–43.
Entezami P, Fox DA, Clapham PJ, Chung KC. Historical perspective on the etiology of rheumatoid arthritis. Hand Clin. 2011;27:1–10. https://doi.org/10.1016/j.hcl.2010.09.006.
Winchester R. A golden anniversary: recognition that rheumatoid arthritis sera contain autoantibodies specific for determinants on native IgG molecules. J Immunol. 2007;178:1227–8.
Tan EM, Smolen JS. Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor. J Exp Med. 2016;213:1937–50. https://doi.org/10.1084/jem.20160792.
Franklin EC, Holman HR, Muller-Eberhard HJ, Kunkel HG. An unusual protein component of high molecular weight in the serum of certain patients with rheumatoid arthritis. J Exp Med. 1957;105:425–38.
Nienhuis RL, Mandema EA. New serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann Rheum Dis. 1964;23:302–5.
Sebbag M, et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1995;95:2672–9. https://doi.org/10.1172/jci117969.
Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ. Anti-keratin antibodies in rheumatoid arthritis. Br Med J. 1979;2:97–9.
Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101:273–81. https://doi.org/10.1172/jci1316.
Girbal-Neuhauser E, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol. 1999;162:585–94.
Malmstrom V, Catrina AI, Klareskog L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Immunol. 2017;17:60–75. https://doi.org/10.1038/nri.2016.124.
Shi J, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A. 2011;108:17372–7. https://doi.org/10.1073/pnas.1114465108.
Juarez M, et al. Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann Rheum Dis. 2016;75:1099–107. https://doi.org/10.1136/annrheumdis-2014-206785.
Trouw LA, Rispens T, Toes REM. Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis. Nat Rev Rheumatol. 2017;13:331–9. https://doi.org/10.1038/nrrheum.2017.15.
Nielen MM, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50:380–6. https://doi.org/10.1002/art.20018.
Catrina AI, Ytterberg AJ, Reynisdottir G, Malmstrom V, Klareskog L. Lungs, joints and immunity against citrullinated proteins in rheumatoid arthritis. Nat Rev Rheumatol. 2014;10:645–53. https://doi.org/10.1038/nrrheum.2014.115.
Catrina AI, Joshua V, Klareskog L, Malmstrom V. Mechanisms involved in triggering rheumatoid arthritis. Immunol Rev. 2016;269:162–74. https://doi.org/10.1111/imr.12379.
Catrina AI, Svensson CI, Malmstrom V, Schett G, Klareskog L. Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis. Nat Rev Rheumatol. 2017;13:79–86. https://doi.org/10.1038/nrrheum.2016.200.
Van de Wiele T, Van Praet JT, Marzorati M, Drennan MB, Elewaut D. How the microbiota shapes rheumatic diseases. Nat Rev Rheumatol. 2016;12:398–411. https://doi.org/10.1038/nrrheum.2016.85.
Astorga GP, Williams RC Jr. Altered reactivity in mixed lymphocyte culture of lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum. 1969;12:547–54.
McMichael AJ, Sasazuki T, McDevitt HO, Payne RO. Increased frequency of HLA-Cw3 and HLA-Dw4 in rheumatoid arthritis. Arthritis Rheum. 1977;20:1037–42.
Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med. 1978;298:869–71. https://doi.org/10.1056/nejm197804202981602.
Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987;30:1205–13.
Raychaudhuri S, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet. 2012;44:291–6. https://doi.org/10.1038/ng.1076.
Hill JA, et al. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1∗0401 MHC class II molecule. J Immunol. 2003;171:538–41.
Scally SW, et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med. 2013;210:2569–82. https://doi.org/10.1084/jem.20131241.
Okada Y, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506:376–81. https://doi.org/10.1038/nature12873.
Viatte S, Plant D, Raychaudhuri S. Genetics and epigenetics of rheumatoid arthritis. Nat Rev Rheumatol. 2013;9:141–53. https://doi.org/10.1038/nrrheum.2012.237.
Karlson EW, et al. Cumulative association of 22 genetic variants with seropositive rheumatoid arthritis risk. Ann Rheum Dis. 2010;69:1077–85. https://doi.org/10.1136/ard.2009.120170.
Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46:183–96. https://doi.org/10.1016/j.immuni.2017.02.006.
Barturen G, Beretta L, Cervera R, Van Vollenhoven R, Alarcon-Riquelme ME. Moving towards a molecular taxonomy of autoimmune rheumatic diseases. Nat Rev Rheumatol. 2018;14:180. https://doi.org/10.1038/nrrheum.2018.23.
Padyukov L, et al. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis. 2011;70:259–65. https://doi.org/10.1136/ard.2009.126821.
Viatte S, et al. Replication of associations of genetic loci outside the HLA region with susceptibility to anti-cyclic citrullinated peptide-negative rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1603–13. https://doi.org/10.1002/art.39619.
Okada Y, Eyre S, Suzuki A, Kochi Y, Yamamoto K. Genetics of rheumatoid arthritis: 2018 status. Ann Rheum Dis. 2018; https://doi.org/10.1136/annrheumdis-2018-213678.
Maurano MT, et al. Systematic localization of common disease-associated variation in regulatory DNA. Science (New York, NY). 2012;337:1190–5. https://doi.org/10.1126/science.1222794.
Chakravarty SD, Poulikakos PI, Ivashkiv LB, Salmon JE, Kalliolias GD. Kinase inhibitors: a new tool for the treatment of rheumatoid arthritis. Clin Immunol. 2013;148:66–78. https://doi.org/10.1016/j.clim.2013.04.007.
Frisell T, Saevarsdottir S, Askling J. Family history of rheumatoid arthritis: an old concept with new developments. Nat Rev Rheumatol. 2016;12:335–43. https://doi.org/10.1038/nrrheum.2016.52.
Alpizar-Rodriguez D, Finckh A. Environmental factors and hormones in the development of rheumatoid arthritis. Semin Immunopathol. 2017;39:461–8. https://doi.org/10.1007/s00281-017-0624-2.
Vessey MP, Villard-Mackintosh L, Yeates D. Oral contraceptives, cigarette smoking and other factors in relation to arthritis. Contraception. 1987;35:457–64.
Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum. 2004;50:3085–92. https://doi.org/10.1002/art.20553.
Kallberg H, et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet. 2007;80:867–75. https://doi.org/10.1086/516736.
Linn-Rasker SP, et al. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis. 2006;65:366–71. https://doi.org/10.1136/ard.2005.041079.
Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12:49–62. https://doi.org/10.1038/nrrheum.2015.169.
Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989;2:244–7.
Haworth C, et al. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol. 1991;21:2575–9. https://doi.org/10.1002/eji.1830211039.
Elliott MJ, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36:1681–90.
Charles P, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999;163:1521–8.
Schett G, Elewaut D, McInnes IB, Dayer JM, Neurath MF. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med. 2013;19:822–4. https://doi.org/10.1038/nm.3260.
Burmester GR, et al. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2017;76:1020–30. https://doi.org/10.1136/annrheumdis-2016-210624.
Kalliolias GD, Liossis SN. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still’s disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs. 2008;17:349–59. https://doi.org/10.1517/13543784.17.3.349.
Genovese MC, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis. 2013;72:863–9. https://doi.org/10.1136/annrheumdis-2012-201601.
Smolen JS, et al. A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Ann Rheum Dis. 2017;76:831–9. https://doi.org/10.1136/annrheumdis-2016-209831.
Shim JH, Stavre Z, Gravallese EM. Bone loss in rheumatoid arthritis: basic mechanisms and clinical implications. Calcif Tissue Int. 2018;102:533–46. https://doi.org/10.1007/s00223-017-0373-1.
Takayanagi H. New developments in osteoimmunology. Nat Rev Rheumatol. 2012;8:684–9. https://doi.org/10.1038/nrrheum.2012.167.
Lacey DL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165–76.
Gravallese EM, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000;43:250–8. https://doi.org/10.1002/1529-0131(200002)43:2<250::Aid-anr3>3.0.Co;2-p.
Takayanagi H, et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2000;43:259–69. https://doi.org/10.1002/1529-0131(200002)43:2<259::Aid-anr4>3.0.Co;2-w.
Kotake S, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 2001;44:1003–12. https://doi.org/10.1002/1529-0131(200105)44:5<1003::Aid-anr179>3.0.Co;2-#.
Gravallese EM, et al. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol. 1998;152:943–51.
Cohen SB, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;58:1299–309. https://doi.org/10.1002/art.23417.
Kleyer A, et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis. 2014;73:854–60. https://doi.org/10.1136/annrheumdis-2012-202958.
Harre U, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest. 2012;122:1791–802. https://doi.org/10.1172/jci60975.
Krishnamurthy A, et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis. 2016;75:721–9. https://doi.org/10.1136/annrheumdis-2015-208093.
Wigerblad G, et al. Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism. Ann Rheum Dis. 2016;75:730–8. https://doi.org/10.1136/annrheumdis-2015-208094.
Negishi-Koga T, et al. Immune complexes regulate bone metabolism through FcRgamma signalling. Nat Commun. 2015;6:6637. https://doi.org/10.1038/ncomms7637.
Harre U, et al. Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat Commun. 2015;6:6651. https://doi.org/10.1038/ncomms7651.
Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol. 2012;8:656–64. https://doi.org/10.1038/nrrheum.2012.153.
Walsh NC, et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res. 2009;24:1572–85. https://doi.org/10.1359/jbmr.090320.
Matzelle MM, et al. Resolution of inflammation induces osteoblast function and regulates the Wnt signaling pathway. Arthritis Rheum. 2012;64:1540–50. https://doi.org/10.1002/art.33504.
Baum R, Gravallese EM. Impact of inflammation on the osteoblast in rheumatic diseases. Curr Osteoporos Rep. 2014;12:9–16. https://doi.org/10.1007/s11914-013-0183-y.
Diarra D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13:156–63. https://doi.org/10.1038/nm1538.
Wang SY, et al. Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. J Rheumatol. 2011;38:821–7. https://doi.org/10.3899/jrheum.100089.
Heiland GR, et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis. 2010;69:2152–9. https://doi.org/10.1136/ard.2010.132852.
Chen XX, et al. Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis. Ann Rheum Dis. 2013;72:1732–6. https://doi.org/10.1136/annrheumdis-2013-203345.
Lee DM, et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science (New York, NY). 2007;315:1006–10. https://doi.org/10.1126/science.1137306.
Muller-Ladner U, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol. 1996;149:1607–15.
Lefevre S, et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med. 2009;15:1414–20. https://doi.org/10.1038/nm.2050.
Bucala R, Ritchlin C, Winchester R, Cerami A. Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. J Exp Med. 1991;173:569–74.
Lee A, et al. Tumor necrosis factor alpha induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 2013;65:928–38. https://doi.org/10.1002/art.37853.
Nakano K, Whitaker JW, Boyle DL, Wang W, Firestein GS. DNA methylome signature in rheumatoid arthritis. Ann Rheum Dis. 2013;72:110–7. https://doi.org/10.1136/annrheumdis-2012-201526.
Ai R, et al. DNA Methylome signature in synoviocytes from patients with early rheumatoid arthritis compared to synoviocytes from patients with longstanding rheumatoid arthritis. Arthritis Rheumatol. 2015;67:1978–80. https://doi.org/10.1002/art.39123.
Karouzakis E, Gay RE, Michel BA, Gay S, Neidhart M. DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 2009;60:3613–22. https://doi.org/10.1002/art.25018.
Sohn C, et al. Prolonged tumor necrosis factor alpha primes fibroblast-like synoviocytes in a gene-specific manner by altering chromatin. Arthritis Rheumatol. 2015;67:86–95. https://doi.org/10.1002/art.38871.
Ai R, et al. Comprehensive epigenetic landscape of rheumatoid arthritis fibroblast-like synoviocytes. Nat Commun. 2018;9:1921. https://doi.org/10.1038/s41467-018-04310-9.
Doody KM, Bottini N, Firestein GS. Epigenetic alterations in rheumatoid arthritis fibroblast-like synoviocytes. Epigenomics. 2017;9:479–92. https://doi.org/10.2217/epi-2016-0151.
Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol. 2013;9:24–33. https://doi.org/10.1038/nrrheum.2012.190.
McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389:2328–37. https://doi.org/10.1016/s0140-6736(17)31472-1.
Feldmann M, Williams RO, Paleolog E. What have we learnt from targeted anti-TNF therapy? Ann Rheum Dis. 2010;69(Suppl 1):i97–9. https://doi.org/10.1136/ard.2009.117143.
Dakin SG, et al. Pathogenic stromal cells as therapeutic targets in joint inflammation. Nat Rev Rheumatol. 2018;14:714–26. https://doi.org/10.1038/s41584-018-0112-7.
Arend WP, Firestein GS. Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis. Nat Rev Rheumatol. 2012;8:573–86. https://doi.org/10.1038/nrrheum.2012.134.
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205–19. https://doi.org/10.1056/NEJMra1004965.
Smolen JS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. https://doi.org/10.1038/nrdp.2018.1.
Noss EH, Brenner MB. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol Rev. 2008;223:252–70. https://doi.org/10.1111/j.1600-065X.2008.00648.x.
Matsumoto I, et al. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat Immunol. 2002;3:360–5. https://doi.org/10.1038/ni772.
Schett G, Firestein GS. Mr outside and Mr inside: classic and alternative views on the pathogenesis of rheumatoid arthritis. Ann Rheum Dis. 2010;69:787–9. https://doi.org/10.1136/ard.2009.121657.
Murakami M, et al. Local microbleeding facilitates IL-6- and IL-17-dependent arthritis in the absence of tissue antigen recognition by activated T cells. J Exp Med. 2011;208:103–14. https://doi.org/10.1084/jem.20100900.
Rombouts Y, et al. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann Rheum Dis. 2015;74:234–41. https://doi.org/10.1136/annrheumdis-2013-203565.
Ioan-Facsinay A, et al. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum. 2008;58:3000–8. https://doi.org/10.1002/art.23763.
Moll JM, Haslock I, Macrae IF, Wright V. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, the intestinal arthropathies, and Behcet’s syndrome. Medicine. 1974;53:343–64.
Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374:2563–74. https://doi.org/10.1056/NEJMra1406182.
Ritchlin CT, Colbert RA, Gladman D. Psoriatic arthritis. N Engl J Med. 2017;376:957–70. https://doi.org/10.1056/NEJMra1505557.
Peluso R, et al. Enteropathic spondyloarthritis: from diagnosis to treatment. Clin Dev Immunol. 2013;2013:631408. https://doi.org/10.1155/2013/631408.
Schmitt S, Reactive K. Arthritis. Infect Dis Clin N Am. 2017;31:265–77. https://doi.org/10.1016/j.idc.2017.01.002.
Zochling J, Brandt J, Braun J. The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis. Rheumatology (Oxford). 2005;44:1483–91. https://doi.org/10.1093/rheumatology/kei047.
Gmuca S, Weiss PF. Juvenile spondyloarthritis. Curr Opin Rheumatol. 2015;27:364–72. https://doi.org/10.1097/bor.0000000000000185.
Bowness P. HLA-B27. Annu Rev Immunol. 2015;33:29–48. https://doi.org/10.1146/annurev-immunol-032414-112110.
Schett G, et al. Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol. 2017;13:731–41. https://doi.org/10.1038/nrrheum.2017.188.
Gravallese EM, Schett G. Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis. Nat Rev Rheumatol. 2018;14:631–40. https://doi.org/10.1038/s41584-018-0091-8.
Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390:73–84. https://doi.org/10.1016/s0140-6736(16)31591-4.
Sieper J, Braun J, Dougados M, Baeten D. Axial spondyloarthritis. Nat Rev Dis Primers. 2015;1:15013. https://doi.org/10.1038/nrdp.2015.13.
Gladman DD. Editorial: what is peripheral spondyloarthritis? Arthritis Rheumatol. 2015;67:865–8. https://doi.org/10.1002/art.39014.
Sieper J, van der Heijde D. Review: nonradiographic axial spondyloarthritis: new definition of an old disease? Arthritis Rheum. 2013;65:543–51. https://doi.org/10.1002/art.37803.
de BJ, Polman A, de B-M. Hereditary factors in rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 1961;20:215–20.
Brewerton DA, et al. Ankylosing spondylitis and HL-A 27. Lancet. 1973;1:904–7.
Caffrey MF, James DC. Human lymphocyte antigen association in ankylosing spondylitis. Nature. 1973;242:121.
Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med. 1973;288:704–6. https://doi.org/10.1056/nejm197304052881403.
Brown MA, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum. 1997;40:1823–8. https://doi.org/10.1002/1529-0131(199710)40:10<1823::Aid-art15>3.0.Co;2-1.
Brown MA, Kenna T, Wordsworth BP. Genetics of ankylosing spondylitis--insights into pathogenesis. Nat Rev Rheumatol. 2016;12:81–91. https://doi.org/10.1038/nrrheum.2015.133.
Costantino F, Breban M, Garchon HJ. Genetics and functional genomics of Spondyloarthritis. Front Immunol. 2018;9:2933. https://doi.org/10.3389/fimmu.2018.02933.
Burton PR, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007;39:1329–37. https://doi.org/10.1038/ng.2007.17.
Reveille JD, et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet. 2010;42:123–7. https://doi.org/10.1038/ng.513.
Lin Z, et al. A genome-wide association study in Han Chinese identifies new susceptibility loci for ankylosing spondylitis. Nat Genet. 2011;44:73–7. https://doi.org/10.1038/ng.1005.
Cortes A, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet. 2013;45:730–8. https://doi.org/10.1038/ng.2667.
Ellinghaus D, et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet. 2016;48:510–8. https://doi.org/10.1038/ng.3528.
Danoy P, et al. Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn’s disease. PLoS Genet. 2010;6:e1001195. https://doi.org/10.1371/journal.pgen.1001195.
Sarin R, Wu X, Abraham C. Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses. Proc Natl Acad Sci U S A. 2011;108:9560–5. https://doi.org/10.1073/pnas.1017854108.
Vecellio M, et al. The genetic association of RUNX3 with ankylosing spondylitis can be explained by allele-specific effects on IRF4 recruitment that alter gene expression. Ann Rheum Dis. 2016;75:1534–40. https://doi.org/10.1136/annrheumdis-2015-207490.
Jostins L, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–24. https://doi.org/10.1038/nature11582.
Cortes A, et al. Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. Nat Commun. 2015;6:7146. https://doi.org/10.1038/ncomms8146.
Dashti N, Mahmoudi M, Aslani S, Jamshidi A. HLA-B∗27 subtypes and their implications in the pathogenesis of ankylosing spondylitis. Gene. 2018;670:15–21. https://doi.org/10.1016/j.gene.2018.05.092.
Schittenhelm RB, Sivaneswaran S, Lim Kam Sian TC, Croft NP, Purcell AW. Human leukocyte antigen (HLA) B27 allotype-specific binding and candidate arthritogenic peptides revealed through heuristic clustering of data-independent acquisition mass spectrometry (DIA-MS) data. Mol Cell Proteomics. 2016;15:1867–76. https://doi.org/10.1074/mcp.M115.056358.
Lopez de Castro JA. How ERAP1 and ERAP2 shape the peptidomes of disease-associated MHC-I proteins. Front Immunol. 2018;9:2463. https://doi.org/10.3389/fimmu.2018.02463.
Chang SC, Momburg F, Bhutani N, Goldberg AL. The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a “molecular ruler” mechanism. Proc Natl Acad Sci U S A. 2005;102:17107–12. https://doi.org/10.1073/pnas.0500721102.
Faham M, et al. Discovery of T cell receptor beta motifs specific to HLA-B27-positive ankylosing spondylitis by deep repertoire sequence analysis. Arthritis Rheumatol. 2017;69:774–84. https://doi.org/10.1002/art.40028.
May E, et al. CD8 alpha beta T cells are not essential to the pathogenesis of arthritis or colitis in HLA-B27 transgenic rats. J Immunol. 2003;170:1099–105.
Taurog JD, et al. Spondylarthritis in HLA-B27/human beta2-microglobulin-transgenic rats is not prevented by lack of CD8. Arthritis Rheum. 2009;60:1977–84. https://doi.org/10.1002/art.24599.
Khare SD, et al. Spontaneous inflammatory disease in HLA-B27 transgenic mice does not require transporter of antigenic peptides. Clin Immunol. 2001;98:364–9. https://doi.org/10.1006/clim.2000.4984.
Mear JP, et al. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J Immunol. 1999;163:6665–70.
Dangoria NS, et al. HLA-B27 misfolding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum. J Biol Chem. 2002;277:23459–68. https://doi.org/10.1074/jbc.M110336200.
Turner MJ, Delay ML, Bai S, Klenk E, Colbert RA. HLA-B27 up-regulation causes accumulation of misfolded heavy chains and correlates with the magnitude of the unfolded protein response in transgenic rats: implications for the pathogenesis of spondylarthritis-like disease. Arthritis Rheum. 2007;56:215–23. https://doi.org/10.1002/art.22295.
DeLay ML, et al. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum. 2009;60:2633–43. https://doi.org/10.1002/art.24763.
Guiliano DB, et al. Polymorphisms in the F pocket of HLA-B27 subtypes strongly affect assembly, chaperone interactions, and heavy-chain Misfolding. Arthritis Rheumatol. 2017;69:610–21. https://doi.org/10.1002/art.39948.
Zhang Z, et al. Brief report: functional interaction of endoplasmic reticulum Aminopeptidase 2 and HLA-B27 activates the unfolded protein response. Arthritis Rheumatol. 2017;69:1009–15. https://doi.org/10.1002/art.40033.
Ciccia F, et al. Evidence that autophagy, but not the unfolded protein response, regulates the expression of IL-23 in the gut of patients with ankylosing spondylitis and subclinical gut inflammation. Ann Rheum Dis. 2014;73:1566–74. https://doi.org/10.1136/annrheumdis-2012-202925.
Allen RL, O’Callaghan CA, McMichael AJ, Bowness P. Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure. J Immunol. 1999;162:5045–8.
Kollnberger S, et al. HLA-B27 heavy chain homodimers are expressed in HLA-B27 transgenic rodent models of spondyloarthritis and are ligands for paired Ig-like receptors. J Immunol. 2004;173:1699–710.
Kollnberger S, et al. Cell-surface expression and immune receptor recognition of HLA-B27 homodimers. Arthritis Rheum. 2002;46:2972–82. https://doi.org/10.1002/art.10605.
Wong-Baeza I, et al. KIR3DL2 binds to HLA-B27 dimers and free H chains more strongly than other HLA class I and promotes the expansion of T cells in ankylosing spondylitis. J Immunol. 2013;190:3216–24. https://doi.org/10.4049/jimmunol.1202926.
Cauli A, et al. The arthritis-associated HLA-B∗27:05 allele forms more cell surface B27 dimer and free heavy chain ligands for KIR3DL2 than HLA-B∗27:09. Rheumatology (Oxford). 2013;52:1952–62. https://doi.org/10.1093/rheumatology/ket219.
Ridley A, et al. Activation-induced killer cell immunoglobulin-like receptor 3DL2 binding to HLA-B27 licenses pathogenic T cell differentiation in spondyloarthritis. Arthritis Rheumatol. 2016;68:901–14. https://doi.org/10.1002/art.39515.
Mielants H, Veys EM, De Vos M, Cuvelier C. Increased intestinal permeability in ankylosing spondylitis. Gut. 1992;33:1150.
Van Praet L, Jacques P, Van den Bosch F, Elewaut D. The transition of acute to chronic bowel inflammation in spondyloarthritis. Nat Rev Rheumatol. 2012;8:288–95. https://doi.org/10.1038/nrrheum.2012.42.
Taurog JD, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994;180:2359–64.
Rehaume LM, et al. ZAP-70 genotype disrupts the relationship between microbiota and host, leading to spondyloarthritis and ileitis in SKG mice. Arthritis Rheumatol. 2014;66:2780–92. https://doi.org/10.1002/art.38773.
Costello ME, et al. Brief report: intestinal dysbiosis in ankylosing spondylitis. Arthritis Rheumatol. 2015;67:686–91. https://doi.org/10.1002/art.38967.
Breban M, et al. Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Ann Rheum Dis. 2017;76:1614–22. https://doi.org/10.1136/annrheumdis-2016-211064.
Lin P, et al. HLA-B27 and human beta2-microglobulin affect the gut microbiota of transgenic rats. PLoS One. 2014;9:e105684. https://doi.org/10.1371/journal.pone.0105684.
Asquith M, et al. Intestinal metabolites are profoundly altered in the context of HLA-B27 expression and functionally modulate disease in a rat model of spondyloarthritis. Arthritis Rheumatol. 2017;69:1984–95. https://doi.org/10.1002/art.40183.
Ciccia F, Rizzo A, Triolo G. Subclinical gut inflammation in ankylosing spondylitis. Curr Opin Rheumatol. 2016;28:89–96. https://doi.org/10.1097/bor.0000000000000239.
Van Praet L, et al. Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. Ann Rheum Dis. 2014;73:1186–9. https://doi.org/10.1136/annrheumdis-2013-203854.
Van Praet L, et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis. 2013;72:414–7. https://doi.org/10.1136/annrheumdis-2012-202135.
Ciccia F, et al. Interleukin-22 and interleukin-22-producing NKp44+ natural killer cells in subclinical gut inflammation in ankylosing spondylitis. Arthritis Rheum. 2012;64:1869–78. https://doi.org/10.1002/art.34355.
Ciccia F, et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum. 2009;60:955–65. https://doi.org/10.1002/art.24389.
Ciccia F, et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis. 2015;74:1739–47. https://doi.org/10.1136/annrheumdis-2014-206323.
Venken K, et al. RORgammat inhibition selectively targets IL-17 producing iNKT and gammadelta-T cells enriched in Spondyloarthritis patients. Nat Commun. 2019;10:9. https://doi.org/10.1038/s41467-018-07911-6.
Taams LS, Steel KJA, Srenathan U, Burns LA, Kirkham BW. IL-17 in the immunopathogenesis of spondyloarthritis. Nat Rev Rheumatol. 2018;14:453–66. https://doi.org/10.1038/s41584-018-0044-2.
Rizzo A, Guggino G, Ferrante A, Ciccia F. Role of subclinical gut inflammation in the pathogenesis of spondyloarthritis. Front Med. 2018;5:63. https://doi.org/10.3389/fmed.2018.00063.
Gracey E, et al. IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. Ann Rheum Dis. 2016;75:2124–32. https://doi.org/10.1136/annrheumdis-2015-208902.
Colonna M. Innate lymphoid cells: diversity, plasticity, and unique functions in immunity. Immunity. 2018;48:1104–17. https://doi.org/10.1016/j.immuni.2018.05.013.
Paulissen SM, et al. Synovial fibroblasts directly induce Th17 pathogenicity via the cyclooxygenase/prostaglandin E2 pathway, independent of IL-23. J Immunol. 2013;191:1364–72. https://doi.org/10.4049/jimmunol.1300274.
Hasegawa E, et al. IL-23-independent induction of IL-17 from gammadeltaT cells and innate lymphoid cells promotes experimental intraocular neovascularization. J Immunol. 2013;190:1778–87. https://doi.org/10.4049/jimmunol.1202495.
Lee JS, et al. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. Immunity. 2015;43:727–38. https://doi.org/10.1016/j.immuni.2015.09.003.
van Tok MN, et al. The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling. Front Immunol. 2018;9:1550. https://doi.org/10.3389/fimmu.2018.01550.
Yao C, et al. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med. 2009;15:633–40. https://doi.org/10.1038/nm.1968.
Esaki Y, et al. Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2010;107:12233–8. https://doi.org/10.1073/pnas.0915112107.
Boniface K, et al. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med. 2009;206:535–48. https://doi.org/10.1084/jem.20082293.
Sherlock JP, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18:1069–76. https://doi.org/10.1038/nm.2817.
Wang X, Lin Z, Wei Q, Jiang Y, Gu J. Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis. Rheumatol Int. 2009;29:1343–7. https://doi.org/10.1007/s00296-009-0883-x.
Mei Y, et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol. 2011;30:269–73. https://doi.org/10.1007/s10067-010-1647-4.
Taylan A, et al. Evaluation of the T helper 17 axis in ankylosing spondylitis. Rheumatol Int. 2012;32:2511–5. https://doi.org/10.1007/s00296-011-1995-7.
Toussirot E, Laheurte C, Gaugler B, Gabriel D, Saas P. Increased IL-22- and IL-17A-producing mucosal-associated invariant T cells in the peripheral blood of patients with ankylosing spondylitis. Front Immunol. 2018;9:1610. https://doi.org/10.3389/fimmu.2018.01610.
Siebert S, Millar NL, McInnes IB. Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? Ann Rheum Dis. 2018; https://doi.org/10.1136/annrheumdis-2018-213654.
Baeten D, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77:1295–302. https://doi.org/10.1136/annrheumdis-2018-213328.
Deodhar A, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019;71:258–70. https://doi.org/10.1002/art.40728.
Targan SR, et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn’s disease. Am J Gastroenterol. 2016;111:1599–607. https://doi.org/10.1038/ajg.2016.298.
Hueber W, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693–700. https://doi.org/10.1136/gutjnl-2011-301668.
Langley RG, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014;371:326–38. https://doi.org/10.1056/NEJMoa1314258.
Griffiths CE, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541–51. https://doi.org/10.1016/s0140-6736(15)60125-8.
Gordon KB, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:345–56. https://doi.org/10.1056/NEJMoa1512711.
Lebwohl M, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318–28. https://doi.org/10.1056/NEJMoa1503824.
Nash P, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389:2317–27. https://doi.org/10.1016/s0140-6736(17)31429-0.
van der Heijde D, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392:2441–51. https://doi.org/10.1016/s0140-6736(18)31946-9.
Gordon KB, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373:136–44. https://doi.org/10.1056/NEJMoa1501646.
Feagan BG, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389:1699–709. https://doi.org/10.1016/s0140-6736(17)30570-6.
Deodhar A, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2018;391:2213–24. https://doi.org/10.1016/s0140-6736(18)30952-8.
Leonardi CL, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665–74. https://doi.org/10.1016/s0140-6736(08)60725-4.
Davis JC Jr, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48:3230–6. https://doi.org/10.1002/art.11325.
Mease PJ, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385–90. https://doi.org/10.1016/s0140-6736(00)02530-7.
Farrell RJ. Crohn’s disease: not all anti-TNFs are the same! Inflamm Bowel Dis. 2002;8:232–3.
Sandborn WJ, et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088–94.
Foster CS, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003;121:437–40. https://doi.org/10.1001/archopht.121.4.437.
McGonagle D, Lories RJ, Tan AL, Benjamin M. The concept of a “synovio-entheseal complex” and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum. 2007;56:2482–91. https://doi.org/10.1002/art.22758.
Jacques P, et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann Rheum Dis. 2014;73:437–45. https://doi.org/10.1136/annrheumdis-2013-203643.
Cuthbert RJ, et al. Brief report: group 3 innate lymphoid cells in human enthesis. Arthritis Rheumatol. 2017;69:1816–22. https://doi.org/10.1002/art.40150.
Ono T, et al. IL-17-producing gammadelta T cells enhance bone regeneration. Nat Commun. 2016;7:10928. https://doi.org/10.1038/ncomms10928.
van Tok MN, et al. Interleukin-17A inhibition diminishes inflammation and new bone formation in experimental spondyloarthritis. Arthritis Rheumatol. 2019;71:612–25. https://doi.org/10.1002/art.40770.
Croes M, et al. Proinflammatory T cells and IL-17 stimulate osteoblast differentiation. Bone. 2016;84:262–70. https://doi.org/10.1016/j.bone.2016.01.010.
El-Zayadi AA, et al. Interleukin-22 drives the proliferation, migration and osteogenic differentiation of mesenchymal stem cells: a novel cytokine that could contribute to new bone formation in spondyloarthropathies. Rheumatology (Oxford). 2017;56:488–93. https://doi.org/10.1093/rheumatology/kew384.
Yoshida K, et al. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc Natl Acad Sci U S A. 2002;99:4580–5. https://doi.org/10.1073/pnas.062053399.
Zhang X, et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest. 2002;109:1405–15. https://doi.org/10.1172/jci15681.
Chen H, et al. Prostaglandin E2 mediates sensory nerve regulation of bone homeostasis. Nat Commun. 2019;10:181. https://doi.org/10.1038/s41467-018-08097-7.
Maksymowych WP, Elewaut D, Schett G. Motion for debate: the development of ankylosis in ankylosing spondylitis is largely dependent on inflammation. Arthritis Rheum. 2012;64:1713–9. https://doi.org/10.1002/art.34442.
Deodhar A. Spondyloarthropathies: TNF inhibitors and structural damage in ankylosing spondylitis. Nat Rev Rheumatol. 2018;14:5–6. https://doi.org/10.1038/nrrheum.2017.197.
Sieper J, Poddubnyy D. Inflammation, new bone formation and treatment options in axial spondyloarthritis. Ann Rheum Dis. 2014;73:1439–41. https://doi.org/10.1136/annrheumdis-2014-205464.
Boersma JW. Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. Scand J Rheumatol. 1976;5:60–4.
Wanders A, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52:1756–65. https://doi.org/10.1002/art.21054.
Poddubnyy D, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis. 2012;71:1616–22. https://doi.org/10.1136/annrheumdis-2011-201252.
Sieper J, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis. 2016;75:1438–43. https://doi.org/10.1136/annrheumdis-2015-207897.
van der Heijde D, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008;58:1324–31. https://doi.org/10.1002/art.23471.
van der Heijde D, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58:3063–70. https://doi.org/10.1002/art.23901.
van der Heijde D, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009;11:R127. https://doi.org/10.1186/ar2794.
Haroon N, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65:2645–54. https://doi.org/10.1002/art.38070.
Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis. 2014;73:710–5. https://doi.org/10.1136/annrheumdis-2012-202698.
Maas F, et al. Reduction in spinal radiographic progression in ankylosing spondylitis patients receiving prolonged treatment with tumor necrosis factor inhibitors. Arthritis Care Res. 2017;69:1011–9. https://doi.org/10.1002/acr.23097.
Molnar C, et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis. 2018;77:63–9. https://doi.org/10.1136/annrheumdis-2017-211544.
Braun J, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2017;76:1070–7. https://doi.org/10.1136/annrheumdis-2016-209730.
Kampylafka E, et al. Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study. Arthritis Res Ther. 2018;20:153. https://doi.org/10.1186/s13075-018-1653-5.
Ruiz-Heiland G, et al. Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis. Ann Rheum Dis. 2012;71:400–7. https://doi.org/10.1136/ard.2010.148262.
Uderhardt S, et al. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis. 2010;69:592–7. https://doi.org/10.1136/ard.2008.102046.
Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest. 2005;115:1571–9. https://doi.org/10.1172/jci23738.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Kalliolias, G.D., Skokos, D. (2020). Immunological Basis of Inflammatory Arthritides. In: Efthimiou, P. (eds) Absolute Rheumatology Review. Springer, Cham. https://doi.org/10.1007/978-3-030-23022-7_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-23022-7_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-23021-0
Online ISBN: 978-3-030-23022-7
eBook Packages: MedicineMedicine (R0)